Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The study evaluates the ABCB1-genotype dependent efficacy of a quick dose-escalation strategy
within 28 days of treatment with approved antidepressants that are known substrates of the
P-glycoprotein, an efflux pump of the blood-brain barrier expressed by the ABCB1 gene.
Moreover, the study evaluates ABCB1-genotype dependent side-effects of approved
antidepressants that are known substrates of the P-glycoprotein, an efflux pump of the
blood-brain barrier expressed by the ABCB1 gene.